Wave Life Sciences, Inc. (WVE): Cash & Equivalents
$602.07M
As of 2025-12-31
$368.01M
As of 2026-06-30
+89.5%
3-year compound annual growth
+26.7%
5-year compound annual growth
+14.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $602.07M | +99.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $302.08M | +50.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $200.35M | +126.4% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $88.50M | -41.2% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $150.56M | -18.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $184.50M | +25.4% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $147.16M | -15.8% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $174.82M | +22.7% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $142.50M | -5.2% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $150.29M | -6.8% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $161.22M | n/m | 2018-03-12, Balance as of period end |
| 2014-12-31 | $1.05M | +138.7% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $439.0K | n/a | 2016-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $602.07M | +99.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $4.47M | +23.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $9.82M | 0.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
Compare WVE, XLO, BFRI, INBP side by side · Screen every company in Pharmaceutical Preparations ↗